DK0983267T3 - Sulfinamidhydroxamsyreforbindelser med en amidoaromatisk ring - Google Patents
Sulfinamidhydroxamsyreforbindelser med en amidoaromatisk ringInfo
- Publication number
- DK0983267T3 DK0983267T3 DK98911480T DK98911480T DK0983267T3 DK 0983267 T3 DK0983267 T3 DK 0983267T3 DK 98911480 T DK98911480 T DK 98911480T DK 98911480 T DK98911480 T DK 98911480T DK 0983267 T3 DK0983267 T3 DK 0983267T3
- Authority
- DK
- Denmark
- Prior art keywords
- amidoaromatic
- hydroxamic acid
- ring
- sulfinamide
- acid compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3979597P | 1997-03-04 | 1997-03-04 | |
EP98911480A EP0983267B1 (en) | 1997-03-04 | 1998-03-04 | Amidoaromatic ring sulfonamide hydroxamic acid compounds |
PCT/US1998/004299 WO1998039329A1 (en) | 1997-03-04 | 1998-03-04 | Amidoaromatic ring sulfonamide hydroxamic acid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0983267T3 true DK0983267T3 (da) | 2005-04-18 |
Family
ID=21907383
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98911479T DK0977745T3 (da) | 1997-03-04 | 1998-03-04 | Thioarylsulfonamidhydroxamsyreforbindelser |
DK98911480T DK0983267T3 (da) | 1997-03-04 | 1998-03-04 | Sulfinamidhydroxamsyreforbindelser med en amidoaromatisk ring |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98911479T DK0977745T3 (da) | 1997-03-04 | 1998-03-04 | Thioarylsulfonamidhydroxamsyreforbindelser |
Country Status (10)
Country | Link |
---|---|
US (1) | US6451791B1 (da) |
EP (2) | EP0977745B1 (da) |
JP (2) | JP2002513409A (da) |
AT (2) | ATE283848T1 (da) |
CA (2) | CA2282399A1 (da) |
DE (2) | DE69827940T2 (da) |
DK (2) | DK0977745T3 (da) |
ES (2) | ES2236893T3 (da) |
PT (1) | PT983267E (da) |
WO (1) | WO1998039329A1 (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6747027B1 (en) | 1996-07-22 | 2004-06-08 | Pharmacia Corporation | Thiol sulfonamide metalloprotease inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6358980B1 (en) | 1999-01-27 | 2002-03-19 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6800646B1 (en) | 1999-02-08 | 2004-10-05 | Pharmacia Corporation | Sulfamato hydroxamic acid metalloprotease inhibitor |
US6869951B1 (en) * | 1999-07-16 | 2005-03-22 | Pharmacia Corporation | Method of changing conformation of a matrix metalloproteinase |
AU6049800A (en) * | 1999-07-16 | 2001-02-05 | G.D. Searle & Co. | Method of changing conformation of a matrix metalloproteinase |
EP1088815A1 (en) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmaceutically active sulfonyl amino acid derivatives |
US6696456B1 (en) | 1999-10-14 | 2004-02-24 | The Procter & Gamble Company | Beta disubstituted metalloprotease inhibitors |
TR200200977T2 (tr) * | 1999-10-14 | 2002-08-21 | The Procter & Gamble Company | Beta konumunda iki kere sübstitüe edilmiş metaloproteaz engelleyiciler |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
PL365444A1 (en) | 2000-03-21 | 2005-01-10 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
WO2001070693A2 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
WO2002003994A1 (en) * | 2000-07-12 | 2002-01-17 | G.D. Searle & Co. | N sulfonyl aminoacid derivatives as inhibitors of metalloproteinase |
PT2087908T (pt) | 2001-06-26 | 2018-07-16 | Amgen Inc | Anticorpos contra opgl |
EP1440057A1 (en) | 2001-11-01 | 2004-07-28 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
AU2003221786A1 (en) | 2002-04-25 | 2003-11-10 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
IL165259A0 (en) | 2002-05-29 | 2005-12-18 | Merck & Co Inc | Compounds useful in the treatment of anthraxa and inhibiting lethal factor |
AU2003304456A1 (en) | 2002-12-23 | 2005-03-16 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
AU2005250351A1 (en) | 2004-05-11 | 2005-12-15 | Merck & Co., Inc. | Process for making n-sulfonated-amino acid derivatives |
ES2380236T3 (es) | 2005-10-28 | 2012-05-09 | Takeda Pharmaceutical Company Limited | Compuesto de amida heterocíclica y uso del mismo |
CA2644783A1 (en) * | 2006-03-29 | 2007-10-18 | Novartis Ag | Selective hydroxamate based mmp inhibitors |
EP2147684A1 (en) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
EP2149568A1 (en) | 2008-07-22 | 2010-02-03 | Bracco Imaging S.p.A | Aryl-sulphonamidic dimers as metalloproteases inhibitors |
US9023318B2 (en) | 2011-06-08 | 2015-05-05 | Siemens Medical Solutions Usa, Inc. | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
EP3717481B1 (en) | 2017-11-27 | 2023-03-01 | Council of Scientific & Industrial Research | Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4337197A (en) | 1980-10-31 | 1982-06-29 | E. R. Squibb & Sons, Inc. | O-sulfated β-lactam hydroxamic acids and intermediates |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5646167A (en) * | 1993-01-06 | 1997-07-08 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamix acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
CN1151157A (zh) * | 1994-06-22 | 1997-06-04 | 英国生物技术药物有限公司 | 金属蛋白酶抑制剂 |
GB9503749D0 (en) * | 1995-02-24 | 1995-04-12 | British Biotech Pharm | Synthesis of hydroxamic acid derivatives |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
DE69624536T2 (de) * | 1995-08-08 | 2003-06-05 | Ono Pharmaceutical Co | Hydroxamsäurederivate verwendbar zur Hemmung von Gelatinase |
AU725831C (en) * | 1995-12-08 | 2002-10-17 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation |
TR199801419T2 (xx) | 1996-01-23 | 1998-10-21 | Shionogi & Co.Ltd. | S�lfone amino asit t�revleri ve ayn� i�erikte metaloproteinez �nleyicileri. |
CA2242416C (en) | 1996-01-23 | 2006-03-21 | Shionogi & Co., Ltd. | Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same |
GB9715962D0 (en) * | 1996-08-23 | 1997-10-01 | Zeneca Ltd | Sulfonamides |
-
1998
- 1998-03-04 US US09/230,205 patent/US6451791B1/en not_active Expired - Fee Related
- 1998-03-04 DK DK98911479T patent/DK0977745T3/da active
- 1998-03-04 CA CA002282399A patent/CA2282399A1/en not_active Abandoned
- 1998-03-04 CA CA002285405A patent/CA2285405A1/en not_active Abandoned
- 1998-03-04 EP EP98911479A patent/EP0977745B1/en not_active Expired - Lifetime
- 1998-03-04 AT AT98911479T patent/ATE283848T1/de not_active IP Right Cessation
- 1998-03-04 ES ES98911480T patent/ES2236893T3/es not_active Expired - Lifetime
- 1998-03-04 DK DK98911480T patent/DK0983267T3/da active
- 1998-03-04 WO PCT/US1998/004299 patent/WO1998039329A1/en active IP Right Grant
- 1998-03-04 PT PT98911480T patent/PT983267E/pt unknown
- 1998-03-04 JP JP53879898A patent/JP2002513409A/ja not_active Ceased
- 1998-03-04 EP EP98911480A patent/EP0983267B1/en not_active Expired - Lifetime
- 1998-03-04 DE DE69827940T patent/DE69827940T2/de not_active Expired - Fee Related
- 1998-03-04 JP JP53879798A patent/JP2002513408A/ja not_active Abandoned
- 1998-03-04 ES ES98911479T patent/ES2234103T3/es not_active Expired - Lifetime
- 1998-03-04 AT AT98911480T patent/ATE287885T1/de not_active IP Right Cessation
- 1998-03-04 DE DE69828783T patent/DE69828783T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6451791B1 (en) | 2002-09-17 |
JP2002513408A (ja) | 2002-05-08 |
WO1998039329A1 (en) | 1998-09-11 |
DE69827940T2 (de) | 2005-06-09 |
JP2002513409A (ja) | 2002-05-08 |
DE69827940D1 (en) | 2005-01-05 |
EP0977745B1 (en) | 2004-12-01 |
EP0983267A4 (en) | 2001-04-11 |
DE69828783D1 (de) | 2005-03-03 |
EP0977745A1 (en) | 2000-02-09 |
EP0983267A1 (en) | 2000-03-08 |
ES2234103T3 (es) | 2005-06-16 |
CA2282399A1 (en) | 1998-09-11 |
EP0983267B1 (en) | 2005-01-26 |
ATE287885T1 (de) | 2005-02-15 |
ES2236893T3 (es) | 2005-07-16 |
DK0977745T3 (da) | 2005-03-14 |
PT983267E (pt) | 2005-06-30 |
ATE283848T1 (de) | 2004-12-15 |
CA2285405A1 (en) | 1998-09-11 |
EP0977745A4 (en) | 2000-05-31 |
DE69828783T2 (de) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0983267T3 (da) | Sulfinamidhydroxamsyreforbindelser med en amidoaromatisk ring | |
ATE254599T1 (de) | Divalente sulfonyl-aryl-oder heteroaryl hydroxamsäureverbindungen | |
AP2001002240A0 (en) | Sufamato hydroxamic acid metalloprotease inhibitor. | |
NZ515197A (en) | Hydroxamic acid derivatives useful as matrix metalloprotease inhibitors | |
DK1030836T3 (da) | Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet | |
YU79901A (sh) | Aromatične sulfon hidroksamične kiseline inhibitor metaloproteaze | |
DE69737605D1 (de) | Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten | |
ID18143A (id) | Penghambat metaloprotease amina siklik tersubstitusi | |
EE05005B1 (et) | Arlpiperasiinid ja nende kasutamine metalloproteinaase (MMP-sid) inhibeerivate agensitena | |
YU85403A (sh) | Aromatični sulfonski hidroksamati i njihova upotreba kao proteaznih inhibitora | |
WO2003007954A3 (en) | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | |
BR9808150A (pt) | Compostos de ácido sulfonil alfa-hidróxi hidroxâmico aromáticos | |
MY141460A (en) | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | |
TH66678A (th) | สารยับยั้งเมทัลโลซีนของกรดซัลฟามาโตไฮดรอกซามิค |